Exchange: NASDAQ·Updated 06:54 PM EDT

SCYX News

News
all
press releases
SCYNEXIS Scores a Potential $214M Government Payday
BARDA awarded SCYNEXIS (NASDAQ:SCYX) a contract worth up to approximately $214 million in potential funding puts SCY-247 at the center of a much bigger public-health and biotech narrative: the race to develop new weapons against increasingly drug-resistant fungal infections.
24-7 Market News
SCYNEXIS Scores a Potential $214M Government Payday
BARDA awarded SCYNEXIS (NASDAQ:SCYX) a contract worth up to approximately $214 million in potential funding puts SCY-247 at the center of a much bigger public-health and biotech narrative: the race to develop new weapons against increasingly drug-resistant fungal infections.
24-7 Market News
More News
Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
Novo has 44 abstracts at EASD, including CagriSema analyses and Phase 2b Zenagamtide results.
Stocktwits
Biotech Week Ahead: XLV Beats The Market — Here Are The Stocks, Readouts And Events To Watch Next
Novo Nordisk (NVO) will hold its 2026 Capital Markets Day in London on Monday.
Stocktwits
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular session. The market value of their outstanding shares is at $2.1 billion. SCYNEXIS (NASDAQ:SCYX) stock increased by 15.7%read more...
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular session. SCYNEXIS (NASDAQ:SCYX) stock moved upwards by 22.54% to $4.57. The market value of their outstanding shares is atread more...
Benzinga
AutoZone, Zscaler And 3 Stocks To Watch Heading Into Tuesday
U.S. stock futures are up, with investor focus on quarterly earnings from AutoZone, Elbit Systems, SCYNEXIS, Box, and Zscaler after the closing bell.read more...
Benzinga
Poxel To Sell PXL770 To Scynexis For Up To $196 Mln; Shares Up
(RTTNews) - Poxel SA (POXEL.PA, PXXLF), a clinical-stage biopharmaceutical company, on Tuesday announced that it has agreed to sell its drug candidate PXL770 to Scynexis, Inc. (SCYX), for up to $196 million...
Nasdaq News: Markets
Scynexis In Spotlight After Poxel Deal, $40 Million Private Placement – SCYX Stock Climbs 2% Pre-Market
The biotech firm announced a deal to acquire a potential treatment for a kidney disease and secured $40 million through a private placement.
Stocktwits
SCYNEXIS Q4 Earnings Assessment
read more...
Benzinga

Advertisement|Remove ads.